Morphin Basi (Morphine Hydrochloride Trihydrate)

Morphin Basi is an opioid analgesic that acts on the mu‑opioid receptor pathway to relieve intense pain.

• Severe acute pain: provides rapid analgesia for patients experiencing intense short‑term pain.
• Post‑operative pain: helps control pain after surgical procedures, facilitating recovery.
• Cancer pain: offers sustained relief for malignant disease‑related discomfort.
• Chronic pain requiring opioid therapy: used when other analgesics are insufficient for long‑term pain management.

• Morphine binds as an agonist to mu‑opioid receptors in the central nervous system, inhibiting the release of neurotransmitters involved in pain transmission. This receptor activation reduces neuronal excitability, leading to decreased perception of pain and increased analgesic and sedative effects.

Morphin Basi may cause a range of adverse reactions.

Common Side Effects

• Nausea: feeling of sickness often accompanied by vomiting.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or reduced alertness.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Sweating: excessive perspiration unrelated to temperature.
• Itching: mild skin pruritus, especially at the injection site.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure leading to faintness.
• Anaphylactic reaction: sudden, severe allergic response with rash, swelling, and airway compromise.
• Adrenal insufficiency: impaired cortisol production causing fatigue and weakness.

When using Morphin Basi, clinicians should observe several safety measures.

• Pain assessment: evaluate severity and type of pain before initiating therapy.
• Respiratory monitoring: regularly check breathing rate and oxygen saturation, especially after dose adjustments.
• Opioid tolerance: assess patient’s prior exposure to opioids to avoid overdose.
• Concomitant CNS depressants: avoid or carefully titrate when combined with benzodiazepines or alcohol.
• Renal/hepatic impairment: consider dose reduction in patients with organ dysfunction.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Morphin Basi can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other opioids: additive respiratory depression and sedation.
• Central nervous system depressants (e.g., benzodiazepines): increased risk of profound sedation.
• Monoamine oxidase inhibitors: potential for severe serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin): may raise morphine plasma levels.
• CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect.
• Diuretics: can enhance hypotensive response.